Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001551959 | SCV001772567 | uncertain significance | not provided | 2024-05-06 | criteria provided, single submitter | clinical testing | Identified in patients with hypermobile-EDS (hEDS) and clinically diagnosed limb girdle muscular dystrophy (LGMD); both patients harbored additional cardiogenetic variants (PMID: 29970176, 35000503); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 29970176, 35000503) |
Fulgent Genetics, |
RCV002476855 | SCV002782202 | uncertain significance | Ehlers-Danlos syndrome due to tenascin-X deficiency; Vesicoureteral reflux 8 | 2021-12-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004039298 | SCV003541006 | uncertain significance | Cardiovascular phenotype | 2023-10-25 | criteria provided, single submitter | clinical testing | The p.R695W variant (also known as c.2083C>T), located in coding exon 2 of the TNXB gene, results from a C to T substitution at nucleotide position 2083. The arginine at codon 695 is replaced by tryptophan, an amino acid with dissimilar properties. This variant was detected in the heterozygous state and co-occurred with variants in other genes in an individual from a limb girdle muscular dystrophy cohort and an individual with hypermobile Ehlers-Danlos syndrome (Rashed ER et al. Vasc Med, 2022 Jun;27:283-289; Fichna JP et al. Hum Genomics, 2018 Jul;12:34). This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV001551959 | SCV005412113 | uncertain significance | not provided | 2024-06-19 | criteria provided, single submitter | clinical testing | BP4 |